

PX3813US
Serial No. 10/018,878

Remarks

Applicants thank the Examiner for the telephone conversation of 21 November 2003. Having reviewed the Examiner's Office Action mailed 4 December 2003, Applicants have now amended the pending claims to conform to the Examiner's suggested amendments.

In the office action, the specification was objected to as containing trademarks that are not capitalized on pages 14-28. After a telephone conversation with the Examiner on 4 March 2004, Applicants learned that the electronic version of the application produced at the Patent Office does not show the capitalization of trademarks present in the Applicants' original application. Accordingly, Applicants have provided a copy of the specification pages 14-29 as originally filed and a copy of corresponding marked specification pages 14-27 showing the trademarks underlined, as requested by the Examiner.

Claims 8, 15, 21, 25, 31, 33, and 36 are objected for clarity and typographical errors. The claims have been amended as suggested.

Claims 7, 24-25, 31, 40, 41, 43 ad 44 are rejected under 35 USC 112 as being indefinite. Claims 7, 21, 31 and 40 have been amended as suggested by the Examiner to clarify the rejected claims.

Claim 49 is rejected by the Examiner under 35 USC 112. Applicants have canceled claim 49.

PX3813US
Serial No. 10/018,878

Applicants submit that the amendments put the claims in condition for allowance and request favorable reconsideration.

Respectfully submitted,



Michael M. Conger
Attorney of Record
Registration No. 43,562

Date: 4 March 2004
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-2474
Facsimile: (919) 483-7988